ALECAlector, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $21M
- 79% YoY
- Operating margin
- -741.3%
- 414% YoY
- EBITDA
- −$150M
- 7.7% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$50M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired127% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $207M | $134M | $97M | $101M | $21M | 79% |
| Operating income | −$37M | −$138M | −$152M | −$145M | −$156M | 7.6% |
| Net income | −$36M | −$133M | −$130M | −$119M | −$143M | 20% |
| Operating cash flow | $299M | −$20M | −$184M | −$230M | −$184M | 20% |
| Capex | $3M | $4M | $2M | $1M | $41K | 97% |
| Stock-based comp | $41M | $46M | $43M | $39M | $27M | 32% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $2M | 17 | 135 |
| FY2024 | $4M | −$2M | 20 | 102 |
| FY2023 | $4M | $3M | 86 | 104 |